Big pharma can only see the benefit of R&D for wealthy markets - There is too little incentive for pharmaceutical companies to work on treatments for diseases of low-income countries
Labels:
#health
No comments
Read More About This Article: http://bit.ly/2Wjxrzz
Subscribe to:
Post Comments
(
Atom
)
No comments :
Post a Comment